Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target of $28.00. The firm highlighted Catalyst Pharma's successful commercialization of drugs for rare neurological diseases as the basis for the positive outlook.

This was the stock's second consecutive day of gains.

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a Outperform recommendation. Analyst Price Forecast Suggests 47.68% Upside As of January 29,